GP3269

GP3269

Identifiers
IUPAC name (2R,3R,4S,5R)-2-[4-(4-fluoroanilino)-5-phenylpyrrolo[2,3-d]pyrimidin-7-yl]-5-methyloxolane-3,4-diol
CAS Number	186393-42-0
PubChem CID	9802216
ChemSpider	7977978
ChEMBL	ChEMBL66277
Chemical and physical data
Formula	C23H21FN4O3
Molar mass	420.444 g·mol−1
3D model (JSmol)	Interactive image
SMILES C[C@@H]1[C@H]([C@H]([C@@H](O1)N2C=C(C3=C(N=CN=C32)NC4=CC=C(C=C4)F)C5=CC=CC=C5)O)O
InChI InChI=1S/C23H21FN4O3/c1-13-19(29)20(30)23(31-13)28-11-17(14-5-3-2-4-6-14)18-21(25-12-26-22(18)28)27-16-9-7-15(24)8-10-16/h2-13,19-20,23,29-30H,1H3,(H,25,26,27)/t13-,19-,20-,23-/m1/s1 Key:MULTXXBUCOCYME-HYYMDVBZSA-N

GP3269 is an experimental drug that acts as a selective inhibitor of the enzyme adenosine kinase. In animal studies it has analgesic and anticonvulsant effects. ^{[1] [2] [3]}

References

1. Erion MD, Ugarkar BG, DaRe J, Castellino AJ, Fujitaki JM, Dixon R, et al. (1997). "Design, Synthesis and Anticonvulsant Activity of the Potent Adenosine Kinase Inhibitor GP3269". Nucleosides and Nucleotides. 16 (7–9): 1013–1021. doi:10.1080/07328319708006124.
2. Bookser BC, Ugarkar BG, Matelich MC, Lemus RH, Allan M, Tsuchiya M, et al. (December 2005). "Adenosine kinase inhibitors. 6. Synthesis, water solubility, and antinociceptive activity of 5-phenyl-7-(5-deoxy-beta-D-ribofuranosyl)pyrrolo[2,3-d]pyrimidines substituted at C4 with glycinamides and related compounds". Journal of Medicinal Chemistry. 48 (24): 7808–7820. doi:10.1021/jm050394a. PMID   16302820.
3. Szentmiklósi AJ, Cseppento A, Harmati G, Nánási PP (2011). "Novel trends in the treatment of cardiovascular disorders: site- and event- selective adenosinergic drugs". Current Medicinal Chemistry. 18 (8): 1164–1187. doi:10.2174/092986711795029753. PMID   21291368.